-->

Stock Power Daily — High-Quality Pharma Stock Captures Powerful Biotech Mega Trend

Post a Comment
Turn Your Images On

High-Quality Pharma Stock Captures Powerful Biotech Mega Trend

  • Biotechnology is one of the most lucrative mega trends of the next decade.

  • The industry is poised to grow revenues 77% by 2026.

  • Today’s Power Stock has been on the front lines of the battle against COVID-19 and rates a 96 out of 100 on our proprietary system.

Biotechnology is where technology and biology meet to advance the field of medicine.

And my team and I are convinced that it’s one of the most lucrative mega trends of the next decade — similar to investing in the internet in the 1990s!

The chart below shows the industry’s exponential growth:

Turn Your Images On

(Click here to view larger image.)

In 2020, the race to find a vaccine for COVID-19 illuminated the importance of biotech. The global industry generated $284 billion.

Experts project that annual revenue will jump 77% by 2026!

Companies — such as today’s excellent Power Stock — rely on advances in biotech to find more effective therapies and to develop vaccines faster.

Click here or on the image below to find out more!

Turn Your Images On


Turn Your Images On

The No. 1 Biotech Investment for 2022…

Mysterious tech could soon “delete” diseases from your body … and make a tiny Silicon Valley company soar high.

Get details now.


Check Out Our Most Recent Power Stocks:


Privacy Policy
The Money & Markets, P.O. Box 8378, Delray Beach, FL 33482.

To ensure that you receive future issues of Money & Markets, please add info@mb.moneyandmarkets.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance.

The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: https://moneyandmarkets.com/contact-us/

Legal Notice: This work is based on what we've learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It's your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Certain investments carry large potential rewards but also large potential risk. Don't trade in these markets with money you can't afford to lose. Money & Markets expressly forbids its writers from having a financial interest in their own securities or commodities recommendations to readers. Such recommendations may be traded, however, by other editors, Money & Markets, its affiliated entities, employees, and agents, but only after waiting 24 hours after an internet broadcast or 72 hours after a publication only circulated through the mail.

(c) 2022 Money & Markets, LLC. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Money & Markets. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 800-684-8471)

Remove your email from this list: Click here to Unsubscribe

Related Posts

There is no other posts in this category.

Post a Comment

Subscribe Our Newsletter